Volume Alert - MRK 59.33 Merck & Company $MRK Hit a high today of 59.69 Closing the day 10:30 at 59.33 -0.56 -0.94% With a day low of 59.13 and a total volume of 1,391,209.
MRK Recent Posts: http://investorshangout.com/Merck--Company-MRK-51867/
MRK Merck & Company Recent Headline News
Global Single Use Bioreactor Market Outlook, 2019: Thermo Fischer Scientific, Sartorius, Merck, GE Healthcare & Pall Corp Dominate the $200+ Million Market
M2 - 1 hr 6 mins ago
Research and Markets (http://www.researchandmarkets.com/research/k5b5rm/single_use) has announced the addition of the "Single Use Bioreactor Market by Product Type, Cell Type, Technology, End User - Global Forecast to 2019" report to their offering. The single use bioreactors (SUBs) market is expected to grow at a double digit CAGR of 18.4% to reach $470.9 million by 2019 from $202.5 million in 2014 Major factors fueling the growth of this market are low requirements of capital investment for setting up the facility, reduced complexity of automation, and energy efficiency. However, regulatory concerns regarding the mixing process, contamination by leachables and extractable, and difficulties in meeting good manufacturing practices (GMP) standards are restricting the growth of the single use bioreactor market. The single use bioreactor market is segmented on the basis of molecule type (monoclonal antibodies (MAbs), vaccines, gene therapy, recombinant proteins, stem cells, and others (growth factors, interferons, antisense, RNA interference)), type of cell (mammalian cell, bacterial cell, yeast cell and others (insect cell and plant cell)), technology (wave-induced motion SUBs, stirred SUBs, single-use bubble column bioreactors, and others (single-use reactors with vertically perforated discs and single-use hybrid reactors)), end users (R&D (CROs, biopharmaceutical manufacturers, and research institutes) and biopharmaceutical manufacturers), and region (North America, Europe, Asia-Pacific, RoW). MAbs is the largest segment of the single use bioreactor market by molecule type. The high growth rate of this segment can be attributed to the growing demand for SUBs in small-scale manufacturing of MAbs as a result of low investment costs, low requirement of manpower, reduction in time-consuming changeover procedures. The mammalian cells segment of the market by type of cell is the largest and fastest-growing segment, owing to successful employment of SUB for mammalian cell cultures for clinical and commercial drug manufacturing. The R&D department of CROs, biopharmaceutical manufacturers, and research institutes is the major end-user segment of the single use bioreactor market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Single Use Bioreactor Market, By Technology 8 Single Use Bioreactor Market, By Molecule Type 9 Single Use Bioreactor Market, By Type Of Cell 10 Single Use Bioreactor Market, By End User 11 Single Use Bioreactor Market, By Geography 12 Competitive Landscape 13 Company Profiles - Applikon Biotechnology - Cellexus Limited - Cellution Biotech - GE Healthcare (Subsidiary Of General Electric Company) - Merck Kgaa - Pall Corporation - Parker Hannifin Corporation - Pbs Biotech, Inc. - Sartorius Ag - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/k5b5rm/single_use
GE: 26.82 (-0.19), PLL: 94.60 (-0.02), MRK: 59.51 (-0.38)
Ezetimibe/simvastatin used in a fixed-dose combination Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
CNW Group - 2 hrs 35 mins ago
Merck, known as MSD outside of Canada and the United States, announced on November 17, 2014, that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine ezetimibe/simvastatin in a fixed-dose combination - the fixed-dose combination of ezetimibe/simvastatin is not available in Canada; the individual components: simvastatin (ZOCOR®) and ezetimibe (EZETROL®) are available in Canada - experienced significantly fewer major cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization) than patients treated with simvastatin alone. The results from this 18,144-patient study of high-risk patients presenting with acute coronary syndromes were presented on November 17 during the late-breaking clinical trials session at the American Heart Association 2014 Scientific Sessions.
MRK: 59.51 (-0.38)
Global Human Microbiome Market Report: Disease, Application & Product Analysis 2014-2019 & 2023
M2 - Wed Nov 19, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/sc2wtl/human_microbiome) has announced the addition of the "Human Microbiome Market by Disease, Application & by Product - Global Forecast to 2023" report to their offering. The human microbiome market is expected to be valued as $294 million in 2019 and is poised to grow at a CAGR of 22.3% within the forecast period of 2019-2023 Moreover, rising incidences of cardiac diseases and other diseases such as diabetes and obesity are also expected to contribute to the growth of the human microbiome market. Increasing side effects and diminishing of human gut flora, due to excessive use of antibiotics, is likely to drive the growth of the human microbiome market. The application market is also expected to be a prominent segment owing to the use of microbiome as diagnostics and therapeutics. The evidence from intransigent research resulted the use of microbiomes as biomarkers and diagnosis of various diseases. The disease segment, on the other hand, will be the fastest-growing segment in the coming years. With the growing incidences and increasing awareness of lifestyle diseases this market is set to grow at a fast pace. The grey area while estimating the market size was the uncertainty factor that lies with the current regulatory scenario for various products. The insights were provided by the industry experts who later clarified as to which disease segment will witness product approvals by the regulatory authorities and will enter the market in the future. Scope of the Report - Disease (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) - Application (Therapeutic, Diagnostic) - Product (Probiotic, Prebiotic, Food, Medical Food, Supplement, Device, Drug) Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Human Microbiome Market, By Disease 8 Human Microbiome Market, By Application 9 Market, By Product 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles - E. I. Du Pont De Nemours And Company - Enterome Bioscience - Merck & Co., Inc. - Metabiomics Corporation - Microbiome Therapeutics Llc. - Osel Inc. - Second Genome, Inc. - Vedanta Biosciences - Vithera Pharmaceuticals - Yakult Honsha Co., Ltd. For more information visit http://www.researchandmarkets.com/research/sc...microbiome
MRK: 59.51 (-0.38)
Gilead's Value Without Its Hep C Franchise
Tim Harrison - at Seeking Alpha - Tue Nov 18, 3:07PM CST
JNJ: 108.29 (-0.54), GILD: 102.17 (-1.54), MRK: 59.51 (-0.38), AMGN: 162.78 (+0.54), ABBV: 65.57 (-0.48), BMY: 58.57 (-0.13), CELG: 107.43 (+0.65)
Merck IMPROVEs-IT Causing These Biotechs' Stock Prices to Improve Too
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 18, 3:00PM CST
Pop quiz: Which one of these drug companies released major positive clinical trial data yesterday? Company Intraday Increase Monday from Friday's Close Merck 1.4% Regeneron Pharmaceuticals 3.3% ...
ESPR: 31.91 (-0.61), MRK: 59.51 (-0.38), REGN: 416.85 (+3.63)
Product and Pipeline Analysis of the Global Vaccines Market : Expected Launches in the Areas of Cancer and Allergies Will Drive Growth
PR Newswire - Tue Nov 18, 11:03AM CST
Executive Summary
MRK: 59.51 (-0.38), GSK: 46.37 (+0.09), NVS: 95.70 (+0.12)
Sanofi: Recent Plunge Is A Buying Opportunity
Nicholas Kitonyi - at Seeking Alpha - Tue Nov 18, 8:00AM CST
NVO: 44.74 (+0.52), PFE: 30.35 (-0.24), MRK: 59.51 (-0.38), LLY: 67.11 (-0.67), SNY: 48.31 (-0.05), MNKD: 6.55 (-0.05)
Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:30PM CST
Merck's (MRK) anti-PD-1 therapy, Keytruda, met the primary endpoint of progression free survival as compared to chemotherapy in a phase II study (KEYNOTE-002).
AGN: 213.14 (-0.23), MRK: 59.51 (-0.38), ABBV: 65.57 (-0.48), BMY: 58.57 (-0.13)
Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
DRTX: 24.16 (+0.41), AGN: 213.14 (-0.23), ACT: 268.17 (-1.43), VRX: 142.05 (+0.11), MRK: 59.51 (-0.38), VRX.TO: 161.13 (+0.71)
Merck PD-1 inhibitor extends PFS in melanoma
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 2:59PM CST
MRK: 59.51 (-0.38)
Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 108.29 (-0.54), GILD: 102.17 (-1.54), GERN: 3.17 (unch), MRK: 59.51 (-0.38), AZN: 75.37 (+1.39), PFE: 30.35 (-0.24), INCY: 71.40 (+1.76), BMY: 58.57 (-0.13), CTIC: 2.23 (-0.05), NVS: 95.70 (+0.12)
Merck (MRK) Breaks Through Resistance at $59.49
Comtex SmarTrend(R) - Mon Nov 17, 2:47PM CST
Merck (NYSE:MRK) has opened bullishly above the pivot of $59.13 today and has reached the first level of resistance at $59.49. Should the shares continue to rise, the resistance pivots of $59.91 and $60.69 will be of interest.
MRK: 59.51 (-0.38)
Will Merck (MRK) Stock Be Helped Today by Zetia Study?
at The Street - Mon Nov 17, 1:53PM CST
Shares of Merck (MRK) are up after the embattled drug Zetia proved effective at reducing the risk of heart attacks, strokes and other heart problems in a large, long-awaited trial.
MRK: 59.51 (-0.38)
Nopras Technologies Inc. Appoints Director Of Business Development - East Coast Operations
PR Newswire - Mon Nov 17, 1:32PM CST
Nopras Technologies (www.nopras-tech.com) has announced the appointment of Stewart B. Rosenberg to the position of Director, Business Development - East Coast Operations. Mr. Rosenberg joins Nopras from Bio-Investigations Ltd., a specialized global venture capital and new business development consultancy he founded 27 years ago, focused in the fields of human, veterinary, and agricultural health care. With undergraduate and graduate degrees in biology, biochemistry, and business from The University of Connecticut, the University of Pennsylvania, and Wharton, Mr. Rosenberg's corporate career began at Centocor (Malvern, PA), now a division of Johnson & Johnson, where he managed the In Vivo Business Unit, and at EMDS (Gibbstown, NJ), then the U.S. subsidiary of E. Merck (Darmstadt, Germany), where he managed Technology / New Ventures. Rosenberg will be geographically located for Nopras on the Eastern U.S. Coast, to particularly address the needs of biotechnology and biopharmaceutical companies heavily focused along the Boston-Washington Corridor. The position carries global responsibility.
JNJ: 108.29 (-0.54), MRK: 59.51 (-0.38)
Merck Drug Works: Vytorin Study Proves Successful
at Investor's Business Daily - Mon Nov 17, 12:35PM CST
Merck (MRK) cholesterol drug Vytorin, an ezetimibe-simvastatin combo, successfully cuts the risk of heart attacks and strokes in high-risk patients more than simvastatin alone, said the drugmaker in its nearly decade-long, 18,144-patient study. "In...
PFE: 30.35 (-0.24), MRK: 59.51 (-0.38), AMGN: 162.78 (+0.54), REGN: 416.85 (+3.63)
Vytorin successful in lowering cardiovascular events versus statin alone
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 12:02PM CST
MRK: 59.51 (-0.38)
Study lifts cloud over heart drugs Zetia, Vytorin
By MARILYNN MARCHIONE - AP - Mon Nov 17, 11:01AM CST
CHICAGO (AP) — A major study lifts a cloud around Zetia and Vytorin, blockbuster drugs for lowering cholesterol. The study found that these pills modestly lower the risk of heart attacks and other problems in people at high risk for them — evidence that's been missing for more than a decade as the drugs racked up billions in sales.
MRK: 59.51 (-0.38)
Cramer: Pfizer Deal With Merck Leaves AstraZeneca In the Cold
at The Street - Mon Nov 17, 10:47AM CST
TheStreet's Jim Cramer says Pfizer's decision to buy Merck's cancer treatment business likely means an acquisition of AstraZeneca is off the table.
SHPG: 208.67 (-1.33), PFE: 30.35 (-0.24), MRK: 59.51 (-0.38), AZN: 75.37 (+1.39), ABBV: 65.57 (-0.48)
VYTORIN(R) (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
Business Wire - Mon Nov 17, 10:45AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN(R) (ezetimibe/simvastatin) - which combines simvastatin with the non-statin ZETIA(R) (ezetimibe) -- experienced significantly fewer major cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization) than patients treated with simvastatin alone. The results from this 18,144-patient study of high-risk patients presenting with acute coronary syndromes were presented today during the late-breaking clinical trials session at the American Heart Association 2014 Scientific Sessions.
MRK: 59.51 (-0.38)
Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 9:14AM CST
OCN: 21.25 (+0.20), KOS: 9.42 (+0.03), KIN: 9.04 (+0.13), VSAT: 65.65 (+0.11), RFMD: 13.69 (-0.06), EBAY: 54.99 (-0.39), TQNT: 22.85 (-0.08), IDIX: 24.50 (+0.05), SEMI: 16.57 (-0.09), VRTV: 50.68 (+2.29), THRX: 13.62 (+0.27), TBPH: 16.49 (+0.03), IMOS: 20.72 (-0.89), ELOS: 9.92 (-0.01), MU: 32.69 (-0.18), AR: 52.91 (+0.76), NCQ: 0.70 (+0.01), PBF: 28.33 (+0.67), LNG: 72.72 (+0.96), ATRA: 26.63 (+0.28), KERX: 15.26 (-0.28), NG: 2.94 (-0.09), AOI: 1.89 (-0.01), FWP: 21.40 (+0.26), BYD: 11.69 (-0.05), ALDW: 17.63 (+0.07), SUNE: 21.28 (-0.20), MRK: 59.51 (-0.38), AVEO: 0.99 (+0.04), AIG: 54.03 (+0.14)
MRK Recent Posts: http://investorshangout.com/Merck--Company-MRK-51867/
MRK Merck & Company Recent Headline News
Global Single Use Bioreactor Market Outlook, 2019: Thermo Fischer Scientific, Sartorius, Merck, GE Healthcare & Pall Corp Dominate the $200+ Million Market
M2 - 1 hr 6 mins ago
Research and Markets (http://www.researchandmarkets.com/research/k5b5rm/single_use) has announced the addition of the "Single Use Bioreactor Market by Product Type, Cell Type, Technology, End User - Global Forecast to 2019" report to their offering. The single use bioreactors (SUBs) market is expected to grow at a double digit CAGR of 18.4% to reach $470.9 million by 2019 from $202.5 million in 2014 Major factors fueling the growth of this market are low requirements of capital investment for setting up the facility, reduced complexity of automation, and energy efficiency. However, regulatory concerns regarding the mixing process, contamination by leachables and extractable, and difficulties in meeting good manufacturing practices (GMP) standards are restricting the growth of the single use bioreactor market. The single use bioreactor market is segmented on the basis of molecule type (monoclonal antibodies (MAbs), vaccines, gene therapy, recombinant proteins, stem cells, and others (growth factors, interferons, antisense, RNA interference)), type of cell (mammalian cell, bacterial cell, yeast cell and others (insect cell and plant cell)), technology (wave-induced motion SUBs, stirred SUBs, single-use bubble column bioreactors, and others (single-use reactors with vertically perforated discs and single-use hybrid reactors)), end users (R&D (CROs, biopharmaceutical manufacturers, and research institutes) and biopharmaceutical manufacturers), and region (North America, Europe, Asia-Pacific, RoW). MAbs is the largest segment of the single use bioreactor market by molecule type. The high growth rate of this segment can be attributed to the growing demand for SUBs in small-scale manufacturing of MAbs as a result of low investment costs, low requirement of manpower, reduction in time-consuming changeover procedures. The mammalian cells segment of the market by type of cell is the largest and fastest-growing segment, owing to successful employment of SUB for mammalian cell cultures for clinical and commercial drug manufacturing. The R&D department of CROs, biopharmaceutical manufacturers, and research institutes is the major end-user segment of the single use bioreactor market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Single Use Bioreactor Market, By Technology 8 Single Use Bioreactor Market, By Molecule Type 9 Single Use Bioreactor Market, By Type Of Cell 10 Single Use Bioreactor Market, By End User 11 Single Use Bioreactor Market, By Geography 12 Competitive Landscape 13 Company Profiles - Applikon Biotechnology - Cellexus Limited - Cellution Biotech - GE Healthcare (Subsidiary Of General Electric Company) - Merck Kgaa - Pall Corporation - Parker Hannifin Corporation - Pbs Biotech, Inc. - Sartorius Ag - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/k5b5rm/single_use
GE: 26.82 (-0.19), PLL: 94.60 (-0.02), MRK: 59.51 (-0.38)
Ezetimibe/simvastatin used in a fixed-dose combination Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
CNW Group - 2 hrs 35 mins ago
Merck, known as MSD outside of Canada and the United States, announced on November 17, 2014, that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine ezetimibe/simvastatin in a fixed-dose combination - the fixed-dose combination of ezetimibe/simvastatin is not available in Canada; the individual components: simvastatin (ZOCOR®) and ezetimibe (EZETROL®) are available in Canada - experienced significantly fewer major cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization) than patients treated with simvastatin alone. The results from this 18,144-patient study of high-risk patients presenting with acute coronary syndromes were presented on November 17 during the late-breaking clinical trials session at the American Heart Association 2014 Scientific Sessions.
MRK: 59.51 (-0.38)
Global Human Microbiome Market Report: Disease, Application & Product Analysis 2014-2019 & 2023
M2 - Wed Nov 19, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/sc2wtl/human_microbiome) has announced the addition of the "Human Microbiome Market by Disease, Application & by Product - Global Forecast to 2023" report to their offering. The human microbiome market is expected to be valued as $294 million in 2019 and is poised to grow at a CAGR of 22.3% within the forecast period of 2019-2023 Moreover, rising incidences of cardiac diseases and other diseases such as diabetes and obesity are also expected to contribute to the growth of the human microbiome market. Increasing side effects and diminishing of human gut flora, due to excessive use of antibiotics, is likely to drive the growth of the human microbiome market. The application market is also expected to be a prominent segment owing to the use of microbiome as diagnostics and therapeutics. The evidence from intransigent research resulted the use of microbiomes as biomarkers and diagnosis of various diseases. The disease segment, on the other hand, will be the fastest-growing segment in the coming years. With the growing incidences and increasing awareness of lifestyle diseases this market is set to grow at a fast pace. The grey area while estimating the market size was the uncertainty factor that lies with the current regulatory scenario for various products. The insights were provided by the industry experts who later clarified as to which disease segment will witness product approvals by the regulatory authorities and will enter the market in the future. Scope of the Report - Disease (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) - Application (Therapeutic, Diagnostic) - Product (Probiotic, Prebiotic, Food, Medical Food, Supplement, Device, Drug) Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Human Microbiome Market, By Disease 8 Human Microbiome Market, By Application 9 Market, By Product 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles - E. I. Du Pont De Nemours And Company - Enterome Bioscience - Merck & Co., Inc. - Metabiomics Corporation - Microbiome Therapeutics Llc. - Osel Inc. - Second Genome, Inc. - Vedanta Biosciences - Vithera Pharmaceuticals - Yakult Honsha Co., Ltd. For more information visit http://www.researchandmarkets.com/research/sc...microbiome
MRK: 59.51 (-0.38)
Gilead's Value Without Its Hep C Franchise
Tim Harrison - at Seeking Alpha - Tue Nov 18, 3:07PM CST
JNJ: 108.29 (-0.54), GILD: 102.17 (-1.54), MRK: 59.51 (-0.38), AMGN: 162.78 (+0.54), ABBV: 65.57 (-0.48), BMY: 58.57 (-0.13), CELG: 107.43 (+0.65)
Merck IMPROVEs-IT Causing These Biotechs' Stock Prices to Improve Too
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 18, 3:00PM CST
Pop quiz: Which one of these drug companies released major positive clinical trial data yesterday? Company Intraday Increase Monday from Friday's Close Merck 1.4% Regeneron Pharmaceuticals 3.3% ...
ESPR: 31.91 (-0.61), MRK: 59.51 (-0.38), REGN: 416.85 (+3.63)
Product and Pipeline Analysis of the Global Vaccines Market : Expected Launches in the Areas of Cancer and Allergies Will Drive Growth
PR Newswire - Tue Nov 18, 11:03AM CST
Executive Summary
MRK: 59.51 (-0.38), GSK: 46.37 (+0.09), NVS: 95.70 (+0.12)
Sanofi: Recent Plunge Is A Buying Opportunity
Nicholas Kitonyi - at Seeking Alpha - Tue Nov 18, 8:00AM CST
NVO: 44.74 (+0.52), PFE: 30.35 (-0.24), MRK: 59.51 (-0.38), LLY: 67.11 (-0.67), SNY: 48.31 (-0.05), MNKD: 6.55 (-0.05)
Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:30PM CST
Merck's (MRK) anti-PD-1 therapy, Keytruda, met the primary endpoint of progression free survival as compared to chemotherapy in a phase II study (KEYNOTE-002).
AGN: 213.14 (-0.23), MRK: 59.51 (-0.38), ABBV: 65.57 (-0.48), BMY: 58.57 (-0.13)
Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
DRTX: 24.16 (+0.41), AGN: 213.14 (-0.23), ACT: 268.17 (-1.43), VRX: 142.05 (+0.11), MRK: 59.51 (-0.38), VRX.TO: 161.13 (+0.71)
Merck PD-1 inhibitor extends PFS in melanoma
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 2:59PM CST
MRK: 59.51 (-0.38)
Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 108.29 (-0.54), GILD: 102.17 (-1.54), GERN: 3.17 (unch), MRK: 59.51 (-0.38), AZN: 75.37 (+1.39), PFE: 30.35 (-0.24), INCY: 71.40 (+1.76), BMY: 58.57 (-0.13), CTIC: 2.23 (-0.05), NVS: 95.70 (+0.12)
Merck (MRK) Breaks Through Resistance at $59.49
Comtex SmarTrend(R) - Mon Nov 17, 2:47PM CST
Merck (NYSE:MRK) has opened bullishly above the pivot of $59.13 today and has reached the first level of resistance at $59.49. Should the shares continue to rise, the resistance pivots of $59.91 and $60.69 will be of interest.
MRK: 59.51 (-0.38)
Will Merck (MRK) Stock Be Helped Today by Zetia Study?
at The Street - Mon Nov 17, 1:53PM CST
Shares of Merck (MRK) are up after the embattled drug Zetia proved effective at reducing the risk of heart attacks, strokes and other heart problems in a large, long-awaited trial.
MRK: 59.51 (-0.38)
Nopras Technologies Inc. Appoints Director Of Business Development - East Coast Operations
PR Newswire - Mon Nov 17, 1:32PM CST
Nopras Technologies (www.nopras-tech.com) has announced the appointment of Stewart B. Rosenberg to the position of Director, Business Development - East Coast Operations. Mr. Rosenberg joins Nopras from Bio-Investigations Ltd., a specialized global venture capital and new business development consultancy he founded 27 years ago, focused in the fields of human, veterinary, and agricultural health care. With undergraduate and graduate degrees in biology, biochemistry, and business from The University of Connecticut, the University of Pennsylvania, and Wharton, Mr. Rosenberg's corporate career began at Centocor (Malvern, PA), now a division of Johnson & Johnson, where he managed the In Vivo Business Unit, and at EMDS (Gibbstown, NJ), then the U.S. subsidiary of E. Merck (Darmstadt, Germany), where he managed Technology / New Ventures. Rosenberg will be geographically located for Nopras on the Eastern U.S. Coast, to particularly address the needs of biotechnology and biopharmaceutical companies heavily focused along the Boston-Washington Corridor. The position carries global responsibility.
JNJ: 108.29 (-0.54), MRK: 59.51 (-0.38)
Merck Drug Works: Vytorin Study Proves Successful
at Investor's Business Daily - Mon Nov 17, 12:35PM CST
Merck (MRK) cholesterol drug Vytorin, an ezetimibe-simvastatin combo, successfully cuts the risk of heart attacks and strokes in high-risk patients more than simvastatin alone, said the drugmaker in its nearly decade-long, 18,144-patient study. "In...
PFE: 30.35 (-0.24), MRK: 59.51 (-0.38), AMGN: 162.78 (+0.54), REGN: 416.85 (+3.63)
Vytorin successful in lowering cardiovascular events versus statin alone
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 12:02PM CST
MRK: 59.51 (-0.38)
Study lifts cloud over heart drugs Zetia, Vytorin
By MARILYNN MARCHIONE - AP - Mon Nov 17, 11:01AM CST
CHICAGO (AP) — A major study lifts a cloud around Zetia and Vytorin, blockbuster drugs for lowering cholesterol. The study found that these pills modestly lower the risk of heart attacks and other problems in people at high risk for them — evidence that's been missing for more than a decade as the drugs racked up billions in sales.
MRK: 59.51 (-0.38)
Cramer: Pfizer Deal With Merck Leaves AstraZeneca In the Cold
at The Street - Mon Nov 17, 10:47AM CST
TheStreet's Jim Cramer says Pfizer's decision to buy Merck's cancer treatment business likely means an acquisition of AstraZeneca is off the table.
SHPG: 208.67 (-1.33), PFE: 30.35 (-0.24), MRK: 59.51 (-0.38), AZN: 75.37 (+1.39), ABBV: 65.57 (-0.48)
VYTORIN(R) (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
Business Wire - Mon Nov 17, 10:45AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN(R) (ezetimibe/simvastatin) - which combines simvastatin with the non-statin ZETIA(R) (ezetimibe) -- experienced significantly fewer major cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization) than patients treated with simvastatin alone. The results from this 18,144-patient study of high-risk patients presenting with acute coronary syndromes were presented today during the late-breaking clinical trials session at the American Heart Association 2014 Scientific Sessions.
MRK: 59.51 (-0.38)
Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 9:14AM CST
OCN: 21.25 (+0.20), KOS: 9.42 (+0.03), KIN: 9.04 (+0.13), VSAT: 65.65 (+0.11), RFMD: 13.69 (-0.06), EBAY: 54.99 (-0.39), TQNT: 22.85 (-0.08), IDIX: 24.50 (+0.05), SEMI: 16.57 (-0.09), VRTV: 50.68 (+2.29), THRX: 13.62 (+0.27), TBPH: 16.49 (+0.03), IMOS: 20.72 (-0.89), ELOS: 9.92 (-0.01), MU: 32.69 (-0.18), AR: 52.91 (+0.76), NCQ: 0.70 (+0.01), PBF: 28.33 (+0.67), LNG: 72.72 (+0.96), ATRA: 26.63 (+0.28), KERX: 15.26 (-0.28), NG: 2.94 (-0.09), AOI: 1.89 (-0.01), FWP: 21.40 (+0.26), BYD: 11.69 (-0.05), ALDW: 17.63 (+0.07), SUNE: 21.28 (-0.20), MRK: 59.51 (-0.38), AVEO: 0.99 (+0.04), AIG: 54.03 (+0.14)
